Many new drugs that target aberrant but reversible epigenetic modifications have been recently tested in preclinical leukemia models and leukemia cell lines: Schenk et al recently demonstrated that inhibitors of lysine-specific demethylase 1 (LSD1, also known as KDM1A) epigenetically reprogram the cells to make them sensitive to ATRA induced differentiation in AML [85]. Here, KDM1A is linked to acute myeloid leukemia.